Alberta Investment Management Corp raised its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 408.9% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 143,306 shares of the biopharmaceutical company's stock after buying an additional 115,146 shares during the quarter. Alberta Investment Management Corp's holdings in Pfizer were worth $3,631,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in PFE. Clarity Asset Management Inc. acquired a new stake in shares of Pfizer during the 4th quarter worth approximately $27,000. Gould Capital LLC boosted its stake in Pfizer by 97.2% in the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after buying an additional 493 shares in the last quarter. North Capital Inc. acquired a new stake in Pfizer in the 1st quarter valued at $28,000. Bayforest Capital Ltd acquired a new stake in Pfizer in the 1st quarter valued at $28,000. Finally, Bernard Wealth Management Corp. acquired a new stake in Pfizer in the 4th quarter valued at $30,000. Institutional investors and hedge funds own 68.36% of the company's stock.
Pfizer Trading Up 0.9%
NYSE PFE traded up $0.20 on Friday, reaching $23.49. The company had a trading volume of 51,287,529 shares, compared to its average volume of 40,584,816. The stock's 50 day moving average is $24.36 and its 200-day moving average is $24.55. The stock has a market cap of $133.55 billion, a price-to-earnings ratio of 17.02, a PEG ratio of 0.85 and a beta of 0.52. The company has a quick ratio of 0.96, a current ratio of 1.26 and a debt-to-equity ratio of 0.64. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $31.32.
Pfizer Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 7.3%. The ex-dividend date is Friday, July 25th. Pfizer's dividend payout ratio is currently 124.64%.
Analyst Upgrades and Downgrades
Several analysts recently commented on PFE shares. BMO Capital Markets decreased their price target on Pfizer from $36.00 to $30.00 in a research note on Thursday, April 17th. Citigroup boosted their price target on Pfizer from $23.00 to $25.00 and gave the company a "neutral" rating in a research note on Wednesday, April 30th. Cantor Fitzgerald began coverage on Pfizer in a research note on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 price objective on the stock. Berenberg Bank reduced their price objective on Pfizer from $28.00 to $25.00 and set a "hold" rating on the stock in a research note on Thursday, May 29th. Finally, Leerink Partners reduced their price objective on Pfizer from $28.00 to $26.00 and set a "market perform" rating on the stock in a research note on Wednesday, April 30th. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, six have given a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $28.28.
View Our Latest Report on Pfizer
Pfizer Profile
(
Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Featured Articles

Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.